With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

The IA showed clinically meaningful, disease-modifying benefits for TRIKAFTA ® /KAFTRIO ®, including a 76% and 70% reduction in the cumulative annual rate of pulmonary exacerbations in the U.S ...

Trikafta/Kaftrio The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are ...

Through the first half of the year, Vertex reported profits of $1.6 billion, with 89% of its revenue coming from Trikafta (marketed as Kaftrio in Europe).

However, higher Trikafta/Kaftrio sales are likely to have caused sales erosion of Vertex’s other CF drugs. While CF remains the main area of focus, the company saw rapid success in its non-CF ...

Vertex Pharmaceuticals Incorporated today announced that the European Commission has granted approval for the label expansion of KAFTRIO ® in a combination regimen ...

Strong demand for its triple-combination cystic fibrosis therapy, Trikafta/Kaftrio, delivered $2.45 billion in revenue. Management slightly raised its 2024 revenue guidance by about 1% at the ...

About KAFTRIO ® (ivacaftor ... TRIKAFTA can cause serious side effects, including: Liver damage and worsening of liver function in patients with severe liver disease that can be serious and may ...

Trikafta/Kaftrio accounted for about 92% of total sales during the quarter. We forecast about $9.85 billion in revenue for 2023, representing growth of 10% over 2022.